...
首页> 外文期刊>Journal of immunoassay and immunochemistry >Immunodetection of collagen types I, II, III, and IV for differentiation of liver fibrosis stages in patients with chronic HCV.
【24h】

Immunodetection of collagen types I, II, III, and IV for differentiation of liver fibrosis stages in patients with chronic HCV.

机译:免疫检测I型,II型,III型和IV型胶原,以区分慢性HCV患者的肝纤维化阶段。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The current study is aimed at evaluating serum collagens and other serum biochemical markers as useful, non-invasive markers of hepatic fibrosis associated with chronic hepatitis C virus (HCV). Collagen types I, II, III, and IV were detected in serum using ELISA and Western blot techniques. The ELISA levels of collagen I, II, III, and IV increased significantly with the progression of fibrosis staging. Based on receiver-operating characteristic (ROC) curve analysis, the collagen type III (70 kDa) and type IV (200 kDa) were more useful than other serum bio-markers for differentiating severe fibrosis from mild fibrosis. Multivariate discriminant analysis (MDA) selected a fibrosis discriminant score (FDS) = [2.345 + Collagen III (microg/mL) x 1.923 + Collagen IV (microg/mL) x 1.544 + ALT (U/mL) x 0.005] - [albumin(g/L) x 0.046]. The FDS correctly classified 87% of the severe fibrosis patients at a cut-off score = 2.2 (i.e., more than 2.2 indicated severe fibrotic liver and less than 2.2 indicated mild fibrotic liver) with specificity of 97%. In a validation study, the FDS was applied to the second cohort of patients and the results were reproduced without significant difference. In conclusion, the developed four-parameter based FDS is useful for identifying severe liver fibrosis in patients with chronic HCV infection.
机译:当前的研究旨在评估血清胶原蛋白和其他血清生化标志物,作为与慢性丙型肝炎病毒(HCV)相关的肝纤维化的有用,非侵入性标志物。使用ELISA和Western印迹技术在血清中检测到I,II,III和IV型胶原。随着纤维化分期的进行,胶原蛋白I,II,III和IV的ELISA水平显着增加。根据接受者操作特征(ROC)曲线分析,III型胶原蛋白(70 kDa)和IV型胶原蛋白(200 kDa)比其他血清生物标志物更能区分严重纤维化和轻度纤维化。多元判别分析(MDA)选择的纤维化判别分数(FDS)= [2.345 +胶原蛋白III(微克/毫升)x 1.923 +胶原蛋白IV(微克/毫升)x 1.544 + ALT(U / mL)x 0.005]-[白蛋白(g / L)x 0.046]。 FDS在临界值= 2.2时正确分类了87%的严重纤维化患者(即,大于2.2表示严重纤维化肝,小于2.2表示轻度纤维化肝),特异性为97%。在一项验证研究中,将FDS应用于第二组患者,结果复制无明显差异。总之,开发的基于四参数的FDS可用于鉴定慢性HCV感染患者的严重肝纤维化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号